Photo by atikahakhtar from unsplash
Mycosis fungoides (MF) is a clinical-pathologically heterogeneous group of Cutaneous T-Cell Lymphomas (CTCLs) primarily developing and affecting the skin. PUVA is the gold standard of treatment in early disease reaching… Click to show full abstract
Mycosis fungoides (MF) is a clinical-pathologically heterogeneous group of Cutaneous T-Cell Lymphomas (CTCLs) primarily developing and affecting the skin. PUVA is the gold standard of treatment in early disease reaching up to 71.4% of complete remission. Upon insufficient response or immediate relapse PUVA can be combined with systemic therapies, most commonly retinoids or IFNα2b. This article is protected by copyright. All rights reserved.
Keywords:
puva;
puva interferon;
mycosis fungoides;
combined therapy;
interferon combined;
therapy patients
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!